CC-90011, developed by Celgene, is being evaluated in combination with Venetoclax and Azacitidine for the treatment of relapsed/refractory (R/R) and treatment-naïve acute myeloid leukemia (AML) patients who are not eligible for intensive chemotherapy. The study's termination due to changed business objectives may indicate a strategic pivot by Celgene, potentially impacting their portfolio in hematological malignancies. The competitive landscape includes other therapies targeting AML, particularly those utilizing Venetoclax, which has shown promise in this indication. The combination approach may offer a differentiated therapeutic option, but the termination raises questions about the asset's future in Celgene's pipeline and its potential market entry.